Relationship of PCNA, C-erbB2 and CD44S expression with tumor grade and stage in urothelial carcinomas of the bladder

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 6, 2014, Pages 1516-1523

  Yildirim, Ayhan ^a   Kösem, Mustafa ^b   Sayar, Ilyas ^c   Gelincik, Ibrahim ^d   Yavuz, Alparslan ^e   Bozkurt, Aliseydi ^c   Erkorkmaz, Ünal ^b   Bayram, Irfan ^e  

^a Department of Pathology Diyarbakir Pediatry and Gynecology Hospital ^*  (Turkey)

^b SAKARYA UNIVERSITY   (Turkey)

^c ERZINCAN UNIVERSITY   (Turkey)

^d NAMIK KEMAL UNIVERSITY   (Turkey)

^e YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

C erbB2; CD44; Immunohistochemical study; PCNA; Urothelial carcinomas

Indexed keywords

CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HERMES ANTIGEN;

ADULT; ARTICLE; BLADDER CARCINOMA; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; FEMALE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROTEIN EXPRESSION; SCORING SYSTEM; TRANSITIONAL CELL CARCINOMA;

EID: 84904036546     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Beltran AL, Sauter G, Gasser I, Hartmann A, Schmitz-Dräger J, Helpap B, Ayala AG, Tamboli P, Knowles MA, Sidransky D, Cordon-Cardo C, Jones PA, Cairns P, Simon R, Amin MB and Tyc-zynski JE. Infltrating Urothelial Carcinoma. Eble JN, Sauter G, Epstein JI and Sesterhenn IA (Eds.) Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. World Health Organization Classifcation of Tumours. Lyon: IARC Press; 2004. pp. 93-124.
2. Bostwick DG and Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002; 441: 109-116.
3. Epstein JI, Amin MB, Reuter VR and Mostaf FK. The World Health Organization/International Society of Urological Pathology consensus classifcation of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998; 22: 1435-1448.
4. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61: 1-13.
5. Akiyama T, Sudo C, Ogawara H, Toyoshima K and Yamamoto T. The product of the human C-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986; 232: 1644-1646.
6. Pinto-de-Sausa J, David L, Almeida R, Leitao D, Preto JR, Seixas M and Pimenta A. C-erbB2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 2002; 10: 247-256.
7. Hattori K, Uchida K, Akaza H, Koiso K, Nemoto R and Harada M. Proliferating cell nuclear antigen cyclin in human transitional cell carcinoma. Br J Urol 1995; 75: 162-166.
8. Shiina H, Igawa M, Yagi H, Urakami S, Shiraka-wa H and Ishibe T. Relationship of genetic instability with immunoreactivities for p53 protein and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. Eur Urol 1996; 30: 80-88.
9. Bozlu M, Orhan D, Baltaci S, Yaman O, Elhan AH, Tulunay O, Müftüoǧlu YZ. The prognostic value of proliferating cell nuclear antigen, Ki-67 and nucleolar organizer region in transitional cell carcinoma of the bladder. Int Urol Nephrol 2002; 33: 59-66.
10. Hong RL, Pu YS, Hsieh TS, Chu JS and Lee WJ. Expression of e-cadherin and exon v6- containing isoforms of CD44s and their prognostic values in human transitional cell carcinoma. J Urol 1995; 153: 2025-2028.
11. Ross JS, del Rosario AD, Bui HX, Kallakury BVS, Okby NT and Figge J. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma. Mod Pathol 1996; 9: 854-860.
12. Sugino T, Gorham H, Yoshida K, Bolodeoku J, Nargund V, Cranston D, Goodison S and Tarin D. Progressive Loss of CD44 gene expression in invasive bladder cancer. Am J Pathol 1996; 149: 873-882.
13. Omran OM and Ata HS. CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer. Ultrastruct Pathol 2012; 36: 145-152.
14. Martin TA, Harrison G, Mansel RE and Jiang WG. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003; 46: 165-186.
15. Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC and Böhle A. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 2002; 102: 514-518.
16. Doganay L, Altaner S, Bilgi S, Kaya E, Ekuklu G and Kutlu K. Expression of the cyclin- dependent kinase inhibitor p27 in transitional cell bladder cancers: Is it a good predictor for tu-mor behavior? Int Urol Nephrol 2003; 35: 181-188.
17. McKenney JK, Desai S, Cohen C and Amin MB. Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in situ and Non-neo-plastic Urothelium an Analysis of Cytokeratin 20, p53, and CD44 Antigens. Am J Surg Pathol 2001; 25: 1074-1078.
18. Rauter VE. The Urothelial Tract, Renal Pelvis, Ureter, Urinary Bladder, and Urethra. Mills SE (ed). Sternberg's Diagnostic Surgical Pathology. 5th Ed. Philadelphia: Lippincott Williams & Wilkins; 2010. pp. 1829-1869.
19. Patrick CW, Alan BR, Darracott VE and Alan JW. Campell üroloji. 8th Edition. Saunders Company; 2005. 4: pp. 2723-2784.
20. Oosterhuis JW, Schapers RF, Janssen-Heijnen ML, Pauwels RP, Newling DW and ten Kate F. Histological grading of papillary urothelial carcinoma of the bladder: Prognostic value of the 1998 WHO/ISUP classifcation system and comparison with conventional grading systems. J Clin Pathol 2002; 55: 900-905.
21. Schapers RF, Pauwels RP, Wijnen JT, Arends JW, Thunnissen FB, Coebergh JW, Smeets AW and Bosman FT. A simplified grading method of transitional cell carcinoma of the urinary bladder: Reproducibility, clinica signifcance and comparison with other prognostic parameters. Br J Urol 1994; 73: 625-631.
22. Fujii Y, Fukui I, Kihara K, Tsujii T, Kageyama Y and Oshima H. Late recurrence and progression after a long tumor-free period in primary Ta and T1 bladder cancer. Eur Urol 1999; 36: 309-313.
23. Nguyen PL, Swanson PE, Jaszcs W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J and Niehans GA. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. Am J Clin Pathol 1994; 101: 166-76.
24. Lippenon PK. Interrelationship between expression of p53, proliferating cell nuclear antigen and c-erbB-2 in bladder cancer. Pathobiol 1993; 61: 178-182.
25. Underwood M, Bartlett J, Reeves J, Gardiner DS, Scott R and Cooke T. C-erbB-2 gene amplification: A molecular marker in recurrent bladder tumors? Cancer Res 1995; 55: 2422-2430.
26. Mellon JK, Lunec J, Wright C, Home CH, Kelly P and Neal DE. C-erbB-2 in bladder cancer: Molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155: 321-326.
27. Lipponen P, Eskelinen M, Syrjänen S, Terva-hauta A and Syrjänen K. Use of immunohisto-chemically demonstrated c-erbB-2 oncopro-tein expression as a prognostic factor in transitional cell carcinoma of the urinary bladder. Eur Urol 1996; 20: 238-242.
28. McCann A, Dervan PA, Johnston PA, Gullick WJ and Carney DN. C-erbB-2 oncoprotein expression in primary human tumors. Cancer 1990; 65: 88-92.
29. Bongiovanni L, Arena V, Vecchio FM, Racioppi M, Bassi P and Pierconti F. HER-2 immunohis-tochemical expression as prognostic marker in high-grade T1 bladder cancer (T1G3). Arch Ital Urol Androl 2013; 24: 73-77.
30. Gandour-Edwards R, Lara PN Jr, Folkins AK, La-Salle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002; 95: 1009-15.
31. Desai S, Lim SD, Jimenez RE, Chun T, Keane TE, McKenney JK, Zavala-Pompa A, Cohen C, Young RH and Amin MB. Relationship of cyto-keratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary uro-thelial neoplasia. Mod Pathol 2000; 13: 1315-1323.
32. Lipponen P, Aaltoma S, Kosma VM, Ala-Opas M and Eskelinen M. Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumors and their relation to prognosis during a long-term follow-up. J Pathol 1998; 186: 157-164.
33. Toma V, Hauri D, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Gasser TC, Sauter G and Roth J. Focal loss of CD44s variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 1999; 155: 1427-1432.